Mergers & Acquisitions
Jun. 20, 2014
Valeant appeals to Allergan shareholders in latest bid to trigger a deal
Valeant Pharmaceuticals took its roughly $51 billion unsolicited buyout offer directly to Allergan's shareholders on Wednesday, the latest maneuver in what's become an increasingly complex and contentious hostile takeover bid.
Daily Journal Staff Writer
Valeant Pharmaceuticals International Inc. took its roughly $51 billion unsolicited buyout offer directly to Allergan Inc.'s shareholders on Wednesday, the latest maneuver in what's become an increasingly complex and contentious takeover bid for the Irvine-based Botox maker.
In an effort to circumvent Allergan's board of directors, which has strenuously opposed its would-be acquirer a...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In